Advertisement

Topics

G1 Therapeutics Announces Positive Topline Results from Randomized Phase 2 Trial of Trilaciclib

11:25 EST 20 Dec 2018 | Investing News Network

G1 Therapeutics (Nasdaq:GTHX), a clinical-stage oncology company, today announced positive topline data showing multi-lineage myelopreservation benefits in its randomized, double-blind, placebo-controlled Phase 2 trial evaluating trilaciclib in combination with topotecan as a treatment for 2nd-/3rd-line small cell lung cancer (2/3L SCLC). As quoted in the press release: “This is the third positive Phase 2 trial … Continued

The post G1 Therapeutics Announces Positive Topline Results from Randomized Phase 2 Trial of Trilaciclib appeared first on Investing News Network.

Original Article: G1 Therapeutics Announces Positive Topline Results from Randomized Phase 2 Trial of Trilaciclib

NEXT ARTICLE

More From BioPortfolio on "G1 Therapeutics Announces Positive Topline Results from Randomized Phase 2 Trial of Trilaciclib"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Lung Cancer
Lung cancer is the uncontrolled cell growth in tissues of the lung. Originating in the lungs, this growth may invade adjacent tissues and infiltrate beyond the lungs. Lung cancer, the most common cause of cancer-related death in men and women, is respons...